Dihexa or its analogs were administered 5 minutes after scopolamine, either intracerebroventricularly at doses of 0.1 or 1 nmol), intraperitoneally at doses of 0.05, 0.25, or 0.50 mg/kg, or orally at doses of 1.25 or 2.0 mg/kg
This product is not intended to diagnose, treat, cure, or prevent any disease
The N-terminal hexanoyl cap and specific hydrophobic amino acid sequence (Tyr-Ile-Ahx) were engineered specifically to increase lipophilicity and metabolic stability, allowing Dihexa to cross cell membranes and the blood-brain barrier intact in preclinical models
Dihexa Your Journey Over Time Elevate Your Cognitive Edge Agility Dihexa may support neural pathways involved in learning, memory formation, and cognitive adaptability
In young rats with scopolamine-induced deficits, all tested Dihexa treatment groups significantly improved water maze performance
Dihexa, with its combined N-hexanoic-Tyr-Ile-(6) aminohexanoic amide structure, exhibited a significantly extended half-life of 335.5 9.5 min, confirming that both N- and C-terminal modifications are effective strategies for improving metabolic stability [2]
